King Pharmaceuticals controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile1 entries
2004
SEC investigation into Medicaid billing practices
The Securities and Exchange Commission investigated King's Medicaid billing practices. The scrutiny coincided with Jefferson Gregory's departure as chief executive and the appointment of Brian Markison.